Alectinib use of up to 2 years in adjuvant setting, evaluated in the ALINA study for stage IB-IIIA NSCLC patients with ALK rearrangements, was compared against adjuvant platinum based chemotherapy for 4 cycles and has also shown a considerable prolongation in DFS of 93.6% vs. 63.7% at 2 years with HR 0.24 [23]. Here, ALK is linked to non-small cell lung carcinoma.